http://iet.metastore.ingenta.com
1887

Decreased internalisation of ErbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib

Decreased internalisation of ErbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib

For access to this article, please select a purchase option:

Buy article PDF
$19.95
(plus tax if applicable)
Buy Knowledge Pack
10 articles for $120.00
(plus taxes if applicable)

IET members benefit from discounts to all IET publications and free access to E&T Magazine. If you are an IET member, log in to your account and the discounts will automatically be applied.

Learn more about IET membership 

Recommend Title Publication to library

You must fill out fields marked with: *

Librarian details
Name:*
Email:*
Your details
Name:*
Email:*
Department:*
Why are you recommending this title?
Select reason:
 
 
 
 
 
IEE Proceedings - Systems Biology — Recommend this title to your library

Thank you

Your recommendation has been sent to your librarian.

A majority of gefitinib (IRESSA)-responsive tumours in non-small cell lung cancer have been found to carry mutations in ErbB1. Previously, it has been observed that internalisation-deficient ErbB1 receptors are strong drivers of oncogenesis. Using a computational model of ErbB1 trafficking and signalling, it is found that a deficiency in ErbB1 internalisation is sufficient to explain the observed signalling phenotype of these gefitinib-responsive ErbB1 mutants in lung cancer cell lines. Experimental tests confirm that gefitinib-sensitive cell lines with and without ErbB1 mutations exhibit markedly slower internalisation rates than gefitinib-insensitive cell lines. Moreover, the computational model demonstrates that reduced ErbB1 internalisation rates are mechanistically linked to upregulated AKT signalling. Experimentally it is confirmed that impaired internalisation of ErbB1 is associated with increased AKT activity, which can be blocked by gefitinib. On the basis of these experimental and computational results, it is surmised that gefitinib sensitivity is a marker of a reliance on AKT signalling for cell survival that may be brought about by impaired ErbB1 internalisation.

References

    1. 1)
      • Y. Yarden , M. Sliwkowski . Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. , 127 - 137
    2. 2)
      • A.E. Wakeling , S.P. Guy , J.R. Woodburn , S.E. Ashton , B.J. Curry , A.J. Barker , K.H. Gibson . ZD 1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. , 5749 - 5754
    3. 3)
      • T.J. Lynch , D.W. Bell , R. Sordella , S. Gurubhagavatula , R.A. Okimoto , B.W. Brannigan , P.L. Harris , S.M. Haserlat , J.G. Supko , F.G. Haluska , D.N. Louis , D.C. Christiani , J. Settleman , D.A. Haber . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. , 2129 - 2139
    4. 4)
      • J.G. Paez , P.A. Janne , J.C. Lee , S. Tracy , H. Greulich , S. Gabriel , P. Herman , F.J. Kaye , N. Lindeman , T.J. Boggon , K. Naoki , H. Sasaki , Y. Fujii , M.J. Eck , W.R. Sellers , B.E. Johnson , M. Meyerson . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science , 1497 - 1500
    5. 5)
      • W. Pao , V. Miller , M. Zakowski , J. Doherty , K. Politi , I. Sarkaria , B. Singh , R. Heelan , V. Rusch , L. Fulton , E. Mardis , D. Kupfer , R. Wilson , M. Kris , H. Varmus . EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA , 13306 - 13311
    6. 6)
      • K.H. Yeh , S.H. Yeh , J.P. Wan , Y.C. Shen , A.L. Cheng . Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung. Anticancer Drugs , 739 - 742
    7. 7)
      • X.T. Zhang , L.Y. Li , X.L. Mu , Q.C. Cui , X.Y. Chang , W. Song , S.L. Wang , M.Z. Wang , W. Zhong , L. Zhang . The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann. Oncol. , 1334 - 1342
    8. 8)
      • X.L. Mu , L.Y. Li , X.T. Zhang , M.Z. Wang , R.E. Feng , Q.C. Cui , H.S. Zhou , B.Q. Guo . Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer. Clin. Cancer. Res. , 4289 - 4294
    9. 9)
      • T.Y. Chou , C.H. Chiu , L.H. Li , C.Y. Hsiao , C.Y. Tzen , K.T. Chang , Y.M. Chen , R.P. Perng , S.F. Tsai , C.M. Tsai . Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin. Cancer. Res. , 3750 - 3757
    10. 10)
      • T.J. Lynch . Correlation of molecular markers including mutations with clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with gefitinib, chemotherapy or chemotherapy and gefitinib in IDEAL and INTACT clinical trials. J. Clin. Oncol. Suppl.
    11. 11)
      • D.W. Bell . Epidermal growth factor receptor mutations and gene amplification in non-small cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol.
    12. 12)
      • W. Pao , V.A. Miller . Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J. Clin. Oncol. , 2556 - 2568
    13. 13)
      • P.A. Janne , J.A. Engelman , B.E. Johnson . Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J. Clin. Oncol. , 3227 - 3234
    14. 14)
      • M.S. Tsao , A. Sakurada , J.C. Cutz , C.Q. Zhu , S. Kamel-Reid , J. Squire , I. Lorimer , T. Zhang , N. Liu , M. Daneshmand , P. Marrano , G. da Cunha Santos , A. Lagarde , F. Richardson , L. Seymour , M. Whitehead , K. Ding , J. Pater , F.A. Shepherd . Erlotinib in lung cancer–molecular and clinical predictors of outcome. N. Engl. J. Med. , 133 - 144
    15. 15)
      • M.A. Fabian , W.H. Biggs , D.K. Treiber , C.E. Atteridge , M.D. Azimioara , M.G. Benedetti , T.A. Carter , P. Ciceri , P.T. Edeen , M. Floyd , J.M. Ford , M. Galvin , J.L. Gerlach , R.M. Grotzfeld , S. Herrgard , D.E. Insko , M.A. Insko , A.G. Lai , J.M. Lelias , S.A. Mehta , Z.V. Milanov , A.M. Velasco , L.M. Wodicka , H.K. Patel , P.P. Zarrinkar , D.J. Lockhart . A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. , 329 - 336
    16. 16)
      • R. Sordella , D.W. Bell , D.A. Haber , J. Settleman . Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science , 1163 - 1167
    17. 17)
      • K.A. Lund , L.K. Opresko , C. Starbuck , B.J. Walsh , H.S. Wiley . Quantitative analysis of the endocytic system involved in hormone-induced receptor internalization. J. Biol. Chem. , 15713 - 15723
    18. 18)
      • P.M. Burke , H.S. Wiley . Human mammary epithelial cells rapidly exchange empty EGFR between surface and intracellular pools. J. Cell. Physiol. , 448 - 460
    19. 19)
      • K.S. Kovacina , G.Y. Park , S.S. Bae , A.W. Guzzetta , E. Schaefer , M.J. Birnbaum , R.A. Roth . Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J. Biol. Chem. , 10189 - 10194
    20. 20)
      • B.S. Hendriks , L.K. Opresko , H.S. Wiley , D. Lauffenburger . Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects. Cancer Res. , 1130 - 1137
    21. 21)
      • B.S. Hendriks , L.K. Opresko , H.S. Wiley , D. Lauffenburger . Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels. J. Biol. Chem. , 23343 - 23351
    22. 22)
    23. 23)
      • A. Sorkin , G. Carpenter . Dimerization of internalized epidermal growth factor receptors. J. Biol. Chem. , 23453 - 23460
    24. 24)
      • A.R. French , D.K. Tadaki , S.K. Niyogi , D.A. Lauffenburger . Intracellular trafficking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor/ligand interaction. J. Biol. Chem. , 4334 - 4340
    25. 25)
      • D.A. Lauffenburger , J.J. Lindermann . (1992) Receptors.
    26. 26)
      • M. Offterdinger , V. Georget , A. Girod , P.I. Bastiaens . Imaging phosphorylation dynamics of the EGF receptor. J. Biol. Chem. , 35 , 36972 - 36981
    27. 27)
      • A.R. Asthagiri , D.A. Lauffenburger . A computational study of feedback effects on signal dynamics in a mitogen-activated protein kinase (MAPK) pathway model. Biotechnol. Prog. , 227 - 239
    28. 28)
      • B.N. Kholodenko , O.V. Demin , G. Moehren , J.B. Hoek . Quantification of short term signaling by the epidermal growth factor receptor. J. Biol. Chem. , 30169 - 30181
    29. 29)
      • J.M. Haugh . Localization of receptor-mediated signal transduction pathways: the inside story. Mol. Intervent. , 292 - 307
    30. 30)
      • J.M. Haugh , A.C. Huang , H.S. Wiley , A. Wells , D.A. Lauffenburger . Internalized epidermal growth factor receptors participate in the activation of p21(ras) in fibroblasts. J. Biol. Chem. , 34350 - 34360
    31. 31)
      • M. Hatakeyama , S. Kimura , T. Naka , T. Kawasaki , N. Yumoto , M. Ichikawa , J.H. Kim , K. Saito , M. Saeki , M. Shirouzu , S. Yokoyama , A. Konagaya . A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulin-induced ErbB signalling. Biochem. J. , 451 - 463
    32. 32)
      • G.A. Rodrigues , M. Falasca , Z. Zhang , S.H. Ong , J. Schlessinger . A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling. Mol. Cell. Biol. , 1448 - 1459
    33. 33)
      • B. Schoeberl , C. Eichler-Jonsson , E.D. Gilles , G. Muller . Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nat. Biotechnol. , 370 - 375
    34. 34)
      • J.M. Haugh , T. Meyer . Active EGF receptors have limited access to PtdIns(4,5)P(2) in endosomes: implications for phospholipase C and PI 3-kinase signaling. J. Cell. Sci. , 303 - 310
    35. 35)
      • T. Arao , H. Fukumoto , M. Takeda , T. Tamura , N. Saijo , K. Nishio . Small in-frame deletion in the epidermal growth factor receptor as a target for ZD 6474. Cancer Res. , 9101 - 9104
    36. 36)
      • M. Hickinson , S. Beck , R. McCormack , P.D. Smith , B. Holloway , G. Speake . Increasing our molecular understanding of the clinical response of gefitinib (IRESSA) using pre-clinical in vitro models of lung cancer. Mol. Cancer. Ther.
    37. 37)
      • T. Sorkina , F. Huang , L. Beguinot , A. Sorkin . Effect of tyrosine kinase inhibitors on clathrin-coated pit recruitment and internalization of epidermal growth factor receptor. J. Biol. Chem. , 27433 - 27441
    38. 38)
      • H.S. Wiley , J.J. Herbst , B.J. Walsh , D.A. Lauffenburger , M.G. Rosenfeld , G.N. Gill . The role of tyrosine kinase activity in endocytosis, compartmentation, and down-regulation of the epidermal growth factor receptor. J. Biol. Chem. , 11083 - 11094
    39. 39)
      • M.H. Schmidt , F.B. Furnari , W.K. Cavenee , O. Bogler . Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proc. Natl. Acad. Sci. USA , 6505 - 6510
    40. 40)
      • H.S. Wiley , D.D. Cunningham . The endocytotic rate constant. A cellular parameter for quantitating receptor-mediated endocytosis. J. Biol. Chem. , 4222 - 4229
    41. 41)
      • F. Cappuzzo , E. Magrini , G.L. Ceresoli , S. Bartolini , E. Rossi , V. Ludovini , V. Gregorc , C. Ligorio , A. Cancellieri , S. Damiani , A. Spreafico , C.T. Paties , L. Lombardo , C. Calandri , G. Bellezza , M. Tonato , L. Crino . Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J. Natl. Cancer. Inst. , 1133 - 1141
    42. 42)
      • M.D. Marmor , Y. Yarden . Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene , 2057 - 2070
    43. 43)
      • T. Shimamura , A.M. Lowell , J.A. Engelman , G.I. Shapiro . Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res. , 6401 - 6408
    44. 44)
      • A.V. Vieira , C. Lamaze , S.L. Schmid . Control of EGF receptor signaling by clathrin-mediated endocytosis. Science , 2086 - 2089
    45. 45)
      • A. Wells , J.B. Welsh , C.S. Lazar , H.S. Wiley , G.N. Gill , M.G. Rosenfeld . Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. Science , 962 - 964
    46. 46)
      • D.J. Slamon , G.M. Clark , S.G. Wong , W.J. Levin , A. Ullrich , W.L. McGuire . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science , 177 - 182
    47. 47)
      • S.L. Moulder , F.M. Yakes , S.K. Muthuswamy , R. Bianco , J.F. Simpson , C.L. Arteaga . Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD 1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. , 8887 - 8895
    48. 48)
      • M.M. Moasser , A. Basso , S.D. Averbuch , N. Rosen . The tyrosine kinase inhibitor ZD 1839 (“Iressa”) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. , 7184 - 7188
    49. 49)
      • E.L. Kwak , R. Sordella , D.W. Bell , N. Godin-Heymann , R.A. Okimoto , B.W. Brannigan , P.L. Harris , D.R. Driscoll , P. Fidias , T.J. Lynch , S.K. Rabindran , J.P. McGinnis , A. Wissner , S.V. Sharma , K.J. Isselbacher , J. Settleman , D.A. Haber . Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. USA , 7665 - 7670
    50. 50)
      • J. Amann , S. Kalyankrishna , P.P. Massion , J.E. Ohm , L. Girard , H. Shigematsu , M. Peyton , D. Juroske , Y. Huang , J. Stuart Salmon , Y.H. Kim , J.R. Pollack , K. Yanagisawa , A. Gazdar , J.D. Minna , J.M. Kurie , D.P. Carbone . Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. , 226 - 235
    51. 51)
      • J.A. Engelman , P.A. Janne , C. Mermel , J. Pearlberg , T. Mukohara , C. Fleet , K. Cichowski , B.E. Johnson , L.C. Cantley . ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl. Acad. Sci. USA , 3788 - 3793
    52. 52)
      • H. Waterman , I. Sabanai , B. Geiger , Y. Yarden . Alternative intracellular routing of ErbB receptors may determine signaling potency. J. Biol. Chem. , 13819 - 13827
    53. 53)
      • L.D. Shea , G.M. Omann , J.J. Linderman . Calculation of diffusion-limited kinetics for the reactions in collision coupling and receptor cross-linking. Biophys. J. , 2949 - 2959
http://iet.metastore.ingenta.com/content/journals/10.1049/ip-syb_20050108
Loading

Related content

content/journals/10.1049/ip-syb_20050108
pub_keyword,iet_inspecKeyword,pub_concept
6
6
Loading
This is a required field
Please enter a valid email address